Targeting the MDM2-p53 Interaction with Siremadlin: A Promising Therapeutic Strategy for Treating TP53 Wild-Type Chronic Lymphocytic Leukemia
Erhan Aptullahoğlu, Mohammed Howladar, Jonathan P. Wallis, Helen Marr et autres
4 citationsCancers
Scott Marshall
Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.
67Publications signalées
889Citations signalées
1Affiliations récentes
Institutions déclarées
Domaines associés
Chronic Lymphocytic Leukemia ResearchLymphoma Diagnosis and TreatmentHematopoietic Stem Cell TransplantationCancer-related Molecular PathwaysAcute Myeloid Leukemia Research
Publications récentes
Outcomes with single-agent gilteritinib for relapsed or refractory FLT3 -mutant AML after contemporary induction therapy
Jad Othman, Angela Hwang, Maximillian H. Brodermann, I. Ben Abdallah et autres
12 citationsBlood Advances
RNA Sequencing Reveals Candidate Genes and Pathways Associated with Resistance to MDM2 Antagonist Idasanutlin in TP53 Wild-Type Chronic Lymphocytic Leukemia
Erhan Aptullahoğlu, Sirintra Nakjang, Jonathan P. Wallis, Helen Marr et autres
5 citationsBiomedicines
RNA-Sequencing Reveals Candidate Genes/Pathways Associated with Resistance to MDM2 Antagonist Idasanutlin in TP53 Wild-Type Chronic Lymphocytic Leukemia
John Lunec, Erhan Aptullahoğlu, Sirintra Nakjang, Jonathan P. Wallis et autres
0 citationsResearch Square
Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival in Patients With NPM1 and FLT3 Mutations
Nigel H. Russell, Charlotte S. Wilhelm-Benartzi, Jad Othman, Richard Dillon et autres
46 citationsJournal of Clinical Oncology
Impact of integrating standardized venous thromboembolism (VTE) prophylaxis orders for patients with multiple myeloma into an electronic health record (EHR).
Andrea Janelle Dickens, Victoria Handy, Marti Larriva, Scott Marshall et autres
0 citationsJCO Oncology Practice
Molecular MRD is strongly prognostic in patients with NPM1-mutated AML receiving venetoclax-based nonintensive therapy
Jad Othman, Ing Soo Tiong, Jenny O’Nions, Mike Dennis et autres
73 citationsBlood
SF3B1 Mutations Are Associated with Resistance to Non-Genotoxic MDM2 Inhibition in Chronic Lymphocytic Leukemia
Erhan Aptullahoğlu, Jonathan P. Wallis, Helen Marr, Scott Marshall et autres
11 citationsInternational Journal of Molecular Sciences
Splicing Modulation Results in Aberrant Isoforms and Protein Products of p53 Pathway Genes and the Sensitization of B Cells to Non-Genotoxic MDM2 Inhibition
Erhan Aptullahoğlu, Carmela Ciardullo, Jonathan P. Wallis, Helen Marr et autres
15 citationsInternational Journal of Molecular Sciences
Molecular MRD Assessment Is Strongly Prognostic in Patients with NPM1 Mutated AML Receiving Venetoclax Based Non-Intensive Therapy
Jad Othman, Ing Soo Tiong, Katya Mokretar, Adam Ivey et autres
4 citationsBlood
Real‐world clinical effectiveness and safety of CT‐P10 in patients with diffuse large B‐cell lymphoma: An observational study in Europe
Mark Bishton, Gilles Salles, Camille Golfier, Wolfgang Knauf et autres
2 citationseJHaem
Allogenic haematopoeitic stem cell transplant as cure for severe transfusion‐dependent non‐dominant hereditary spherocytosis due to homozygous SPTA1 mutation
Subramaniam Ramanathan, Wing Roberts, Peter Carey, Scott Marshall et autres
1 citationPediatric Blood & Cancer
BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, ROR et la Banque mondiale, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune donnée externe enregistrée en base. Sources et limites.